Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.44 |
| ▸ | GLS | O94925 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144799 | 0.90 | KDM4E (0.46) | ROCK1GLSKDM4EALDH1A1ROCK2 | |
| SCHEMBL4130775 | 0.88 | MGLL (0.43) | ROCK1GLSKDM4EALDH1A1MMP1 | |
| SCHEMBL4147703 | 0.85 | EPHX2 (0.45) | ROCK1GLSEPHX2 | |
| SCHEMBL13850447 | 0.84 | KDM4E (0.41) | ROCK1GLSKDM4EALDH1A1MMP1 | |
| SCHEMBL4139801 | 0.82 | KDM4E (0.60) | ROCK1GLSKDM4EALDH1A1ROCK2 | |
| SCHEMBL12922895 | 0.80 | GLS (0.61) | ROCK1GLSKDM4EALDH1A1ROCK2 | |
| SCHEMBL14148705 | 0.76 | MGLL (0.46) | GLSKDM4ETP53TSHREPHX2 | |
| SCHEMBL4135597 | 0.74 | TLR7 (0.62) | — | |
| SCHEMBL13849595 | 0.72 | KDM1A (0.55) | GLSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23301972 | 0.71 | EPHX2 (0.48) | KDM4EALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | ROCK1 976/4885GLS 1172/4885KDM4E 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.